Crescita Therapeutics, Inc. (CTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Æterna Zentaris, Inc.

Medicure, Inc.

Crescita Therapeutics, Inc.

Valeo Pharma, Inc.

Resverlogix Corp.

Revive Therapeutics Ltd.

PreveCeutical Medical, Inc.

Core One Labs, Inc.

PharmaTher Holdings Ltd.

Avricore Health, Inc.

XORTX Therapeutics, Inc.

Why is Crescita Therapeutics, Inc. ?

The company has declared negative results in Mar'2026 after 3 consecutive positive quarters

INTEREST(HY) At CAD 0.04 MM has Grown at 40.74%
CASH AND EQV(HY) Lowest at CAD 17.29 MM
DEBT-EQUITY RATIO (HY) Highest at -43.05 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 49.06%, its profits have risen by 119.9% ; the PEG ratio of the company is 0.1

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Crescita Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Crescita Therapeutics, Inc.

49.06%

1.26

71.99%

S&P/TSX 60

29.6%

2.31

12.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.00%

EBIT Growth (5y)

-193.70%

EBIT to Interest (avg)

-0.90

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

1.17

Tax Ratio

0.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.23%

ROE (avg)

2.50%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.02

EV to EBIT

-5.50

EV to EBITDA

6.41

EV to Capital Employed

1.05

EV to Sales

0.28

PEG Ratio

0.12

Dividend Yield

ROCE (Latest)

-19.02%

ROE (Latest)

4.35%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -10.52% (YoY

NET PROFIT(9M)

Higher at CAD -0.19 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.54 times

NET SALES(Q)

At CAD 5.64 MM has Grown at 59.37%

-13What is not working for the Company

INTEREST(HY)

At CAD 0.04 MM has Grown at 40.74%

CASH AND EQV(HY)

Lowest at CAD 17.29 MM

DEBT-EQUITY RATIO (HY)

Highest at -43.05 %

OPERATING PROFIT(Q)

Lowest at CAD -0.82 MM

PRE-TAX PROFIT(Q)

Lowest at CAD -1.16 MM

NET PROFIT(Q)

Lowest at CAD -1.16 MM

EPS(Q)

Lowest at CAD -0.06

Here's what is working for Crescita Therapeutics, Inc.

Net Sales

At CAD 5.64 MM has Grown at 59.37%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Inventory Turnover Ratio

Highest at 2.54 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -10.52% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Crescita Therapeutics, Inc.

Interest

At CAD 0.04 MM has Grown at 40.74%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Operating Profit

Lowest at CAD -0.82 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CAD MM)

Pre-Tax Profit

Lowest at CAD -1.16 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CAD MM)

Net Profit

Lowest at CAD -1.16 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CAD MM)

EPS

Lowest at CAD -0.06

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CAD)

Cash and Eqv

Lowest at CAD 17.29 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -43.05 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio